TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder ...

Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in ...

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

An investigator reported updated findings from the phase 2/3 study QUILT 3.032 using a July 15, 2024 data cutoff.

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) treatment with carcinoma in situ (CIS ...